His research in the Athymic Animal & Xenograft Core Facility at CWRU deals with utilizing human and mouse tumor models, angiogenesis (growth of blood vessels stimulated by tumors) and pharmacokinetics ...

Efficacy, maximal tolerated dose, and toxicokinetics of TTC-352 in rats and dogs, a partial ER agonist for metastatic ER+ breast cancer. Effect of amplification of xenobiotic detoxification pathways ...

Pharmacodynamic phase I study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel. This is an ASCO Meeting Abstract from the 2017 ASCO Annual ...

We are pleased to announce that William Schiemann, PhD has accepted the role of Director of the Case Comprehensive Cancer Center's Athymic Animal and Preclinical Therapeutics Shared Resource.